Abstracts tagged "Wegener’s granulomatosis and systemic vasculitides"

Abstract Number: 1668 • 2019 ACR/ARP Annual Meeting
Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Registry
Michele Iudici¹, Christian Pagnoux ², Delphine Courvoisier ³, Pascal Cohen ⁴, Mohamed Hamidou ⁵, Achille Aouba ⁶, François Lifermann ⁷, Marc Ruivard ⁸, Olivier Aumaitre ⁹, Bernard Bonnotte ¹⁰, François Maurier ¹¹, Olivier Decaux ¹², Eric Hachulla ¹³, Alexandre Karras ¹⁴, Chahéra Khouatra ¹⁵, Noémie Jourde-Chiche ¹⁶, Jean-François Viallard ¹⁷, Claire Blanchard-Delaunay ¹⁸, Pascal Godmer ¹⁹, Alain Le Quellec ²⁰, Thomas Quémeneur ²¹, Claire de Moreuil ²², Alexis Régent ⁴, Benjamin Terrier ⁴, Luc Mouthon ⁴, Loic Guillevin ⁴ and Xavier Puéchal for the French Vasculitis Study Group ⁴, ¹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, France and Division of Rheumatology, Department of Internal Medicine Specialties, Geneva University Hospitals, Switzerland, Geneva, Geneve, Switzerland, ²National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin and Toronto Canada, Paris, France, ³Division of Rheumatology, Geneva University Hospital, Switzerland, Geneva, Switzerland, ⁴National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ⁵CHU Nantes, Nantes, France, ⁶CHU Caen, Caen, France, ⁷CH Dax, Dax, France, ⁸CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁹CHU Clermont Ferrand, Clermont Ferrand, France, ¹⁰Service de Médecine Interne et Immunologie Clinique, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon ; Université Bourgogne-Franche Comté, INSERM, EFS BFC, UMR1098, F-21000 Dijon, Dijon, France, ¹¹Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, ¹²CHU Rennes, Rennes, France, ¹³CHU Lille, Lille, France, ¹⁴Paris HEGP, Paris, France, ¹⁵CHU Lyon, Lyon, France, ¹⁶APHM, Marseille, Marseille, France, ¹⁷CHU Bordeaux, Bordeaux, France, ¹⁸CH Niort, Niort, France, ¹⁹CH Bretagne-Atlantique, Vannes, France, ²⁰CHU Montpellier, Montpellier, France, ²¹CH Valenciennes, Valenciennes, France, ²²CHU Brest, Brest, France
Background/Purpose: The long-term features of granulomatosis with polyangiitis (GPA), a systemic small-vessel ANCA-associated necrotizing vasculitis, have been mainly reported in small patient series. The aim…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].